Skip to main content
Amylyx Pharmaceuticals, Inc. logo

Amylyx Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · AMLX ISIN · US0321085088 US Manufacturing
Filings indexed 383 across all filing types
Latest filing 2024-03-08 Regulatory Filings
Country US United States of America
Listing US AMLX

About Amylyx Pharmaceuticals, Inc.

https://www.amylyx.com/

Amylyx Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative diseases and other conditions with high unmet medical needs. The company's primary therapeutic candidate was AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). In April 2024, following the results of a Phase 3 clinical trial, Amylyx announced it would voluntarily withdraw the marketing authorizations for AMX0035 in the U.S. and Canada. The company is advancing a pipeline of other investigational therapies, utilizing a modality-agnostic approach to match treatments to diseases based on mechanistic rationale and rigorous scientific data.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 8, 2024, by Amylyx Pharmaceuticals, Inc. It announces topline results from a Phase 3 clinical trial (PHOENIX) and includes a press release as an exhibit. The content is primarily an announcement of clinical trial results and company plans, not a full financial report or detailed financial statements. The document is about a current event and regulatory disclosure rather than an annual or quarterly report, audit, or earnings release. It does not contain detailed financial data or management discussion of financial results. The document is a regulatory filing announcing material events and includes a press release, fitting the category of Regulatory Filings (RNS).
2024-03-08 English
4
Director's Dealing
2024-03-07 English
4
Director's Dealing
2024-03-07 English
4
Director's Dealing
2024-03-07 English
4
Director's Dealing
2024-03-07 English
4
Director's Dealing
2024-02-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.